659 related articles for article (PubMed ID: 15544357)
1. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
2. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
Sutherland JS; Bhakta V; Filion ML; Sheffield WP
Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
[TBL] [Abstract][Full Text] [Related]
3. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
[TBL] [Abstract][Full Text] [Related]
4. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786
[TBL] [Abstract][Full Text] [Related]
5. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
Roddick LA; Bhakta V; Sheffield WP
BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
[TBL] [Abstract][Full Text] [Related]
6. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance.
Cunningham MA; Bhakta V; Sheffield WP
Thromb Haemost; 2002 Jul; 88(1):89-97. PubMed ID: 12152684
[TBL] [Abstract][Full Text] [Related]
7. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.
Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S
Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677
[TBL] [Abstract][Full Text] [Related]
8. Role of the P6-P3' region of the serpin reactive loop in the formation and breakdown of the inhibitory complex.
Plotnick MI; Schechter NM; Wang ZM; Liu X; Rubin H
Biochemistry; 1997 Nov; 36(47):14601-8. PubMed ID: 9398179
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity.
Gierczak RF; Bhakta V; Xie M; Sheffield WP
J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel recombinant serpin with potential antithrombotic properties.
Hopkins PC; Crowther DC; Carrell RW; Stone SR
J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
[TBL] [Abstract][Full Text] [Related]
11. Role of Leu99 of thrombin in determining the P2 specificity of serpins.
Rezaie AR
Biochemistry; 1997 Jun; 36(24):7437-46. PubMed ID: 9200692
[TBL] [Abstract][Full Text] [Related]
12. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
Derechin VM; Blinder MA; Tollefsen DM
J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
[TBL] [Abstract][Full Text] [Related]
13. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.
Hamada M; Bhakta V; Andres SN; Sheffield WP
Front Cardiovasc Med; 2021; 8():647405. PubMed ID: 33816577
[TBL] [Abstract][Full Text] [Related]
14. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
15. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity.
Bhakta V; Gierczak RF; Sheffield WP
J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600
[TBL] [Abstract][Full Text] [Related]
16. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
17. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
18. Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase.
Whisstock J; Lesk AM; Carrell R
Proteins; 1996 Nov; 26(3):288-303. PubMed ID: 8953650
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
Stone SR; Le Bonniec BF
J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
